The emergence of pharmacotherapies for cognitive function in Down syndrome

Am J Med Genet A. 2010 Dec;152A(12):3026-7. doi: 10.1002/ajmg.a.33729.
No abstract available

Publication types

  • Comparative Study
  • Comment

MeSH terms

  • Adolescent
  • Child
  • Cholinesterase Inhibitors / adverse effects
  • Cholinesterase Inhibitors / pharmacology
  • Cholinesterase Inhibitors / therapeutic use
  • Clinical Trials as Topic
  • Cognition / drug effects*
  • Donepezil
  • Dose-Response Relationship, Drug
  • Down Syndrome / drug therapy*
  • Down Syndrome / physiopathology
  • Down Syndrome / psychology*
  • Drug Tolerance
  • Humans
  • Indans / adverse effects
  • Indans / pharmacology
  • Indans / therapeutic use
  • Multicenter Studies as Topic
  • Neuropsychological Tests
  • Piperidines / adverse effects
  • Piperidines / pharmacology
  • Piperidines / therapeutic use
  • Randomized Controlled Trials as Topic
  • Time Factors
  • Treatment Outcome

Substances

  • Cholinesterase Inhibitors
  • Indans
  • Piperidines
  • Donepezil